

VEENA VENUGOPALAN, PHARM.D., BCIDP



E-mail: vvenugopalan@cop.ufl.edu

ACADEMIC CREDENTIALS

1999 to 2002	Pre-Pharmacy University of Kentucky Lexington, Kentucky
2002 to 2006	Doctor of Pharmacy Program University of Kentucky, College of Pharmacy Lexington, Kentucky

POST-GRADUATE EDUCATION

2006 to 2007	Pharmacy Post Graduate Year 1 Residency Kelly Smith, Pharm.D. BCPS Residency Program Director University of Kentucky HealthCare Lexington, Kentucky
2007 to 2008	Pharmacy Post Graduate Year 2 Residency Craig Martin, Pharm.D. BCPS Residency Program Director University of Kentucky HealthCare Lexington, Kentucky

PROFESSIONAL LICENSURE OR CERTIFICATION

2006	Kentucky Board of Pharmacy- License # 013394
2016	Florida Board of Pharmacy- License # PS54600
2018	Board Certified Infectious Diseases Pharmacist (BCIDP)
2022	ASHP Diversity, Equity, and Inclusion Certificate

PROFESSIONAL EXPERIENCE

Jul 2008 to Jun 2011

Assistant Professor
Titus Family Department of Clinical Pharmacy and
Pharmaceutical Economics and Policy
University of Southern California, School of Pharmacy
Los Angeles, CA

Clinical Specialist, Infectious Diseases
Los Angeles County Hospital (LAC+USC)
Los Angeles, CA

Aug 2011 to Jul 2014

Pharmacotherapy Specialist, Infectious Diseases
Post Graduate Year 2 Residency Program Director,
Infectious Diseases
The Brooklyn Hospital Center
Brooklyn, NY

Adjunct Clinical Professor
Division of Pharmacy Practice
Arnold & Marie Schwartz College of Pharmacy and Health
Sciences
Long Island University
Brooklyn, NY

Aug 2014 to Nov 2015

Clinical Pharmacy Specialist, Infectious Diseases
Scripps Green Hospital
Scripps Memorial Hospital Encinitas
Scripps Health
San Diego, CA

Jan 2016 to Jul 2019

UF Health
Post Graduate Year 2 Residency Program Director,
Infectious Diseases

Jan 2016 to Present

Clinical Associate Professor
Diversity, Inclusion, and Health Equity Campus
Coordinator
University of Florida
College of Pharmacy
Department of Pharmacotherapy and Translational
Research
Gainesville, FL

TEACHING ACTIVITIES

Dec 2008 to Dec 2010	PHRD 605 Infectious Diseases Therapeutics Module University of Southern California, School of Pharmacy Los Angeles, CA
Jul 2013	PHRM 709E Advanced Microbial Therapy Touro College of Pharmacy New York, NY
Jul 2016 to Present	PHA 5755 Principle of Medical Microbiology, Immunology and Virology University of Florida, College of Pharmacy Gainesville, FL
Jul 2016 to Present	PHA 5782 Introduction to Infectious Diseases, Hematology, and Oncology University of Florida, College of Pharmacy Gainesville, FL
Presentations	
Sep 2010	Infection Control Clinical Update: Bacterial Resistance Mechanism and Antimicrobial Stewardship Infection Control Department Continuing Education Program Los Angeles County Hospital (LAC+USC) Los Angeles, CA
Jan 2012	Antimicrobial Stewardship and Tools for Optimizing Therapy Internal Medicine Grand Rounds Continuing Education Program The Brooklyn Hospital Center Brooklyn, NY
Jan 2013	Updates in The Management of <i>Clostridium difficile</i> Internal Medicine Grand Rounds Continuing Education Program

The Brooklyn Hospital Center
Brooklyn, NY

Aug 2014

Implementation of an Antimicrobial Stewardship Program
(ASP) Initiative to Reduce Time to Initiation of
Antimicrobials in Bacteremic Patients
Antimicrobial Stewardship Forum
Greater New York Hospital Association (GNYHA)-
Continuing Education Program
Brooklyn, NY

Sep 2016

Tools to Help You with Antibiotic Selection: Role of
Penicillin Skin Testing
UF Health Shands
Continuing Education Program
Gainesville, FL

Jun 13

Clinical Utility of Cefepime for the Management of
Bacteremia Secondary to AmpC Producing Organisms
3rd International Caparica Congress in Antibiotic
Resistance
Platform presentation
Caparica, Portugal

June 2019

Antimicrobial Stewardship: Staying ahead of the game
Annual University of Florida Student Science Training
Program (SSTP)
Center for Precollegiate Education and Training
Gainesville, FL

Aug 2019

Therapeutic Drug Monitoring of Beta-Lactams: No Longer
a Shot in the Dark.
Florida Society of Health-System Pharmacists Annual
Meeting
Orland, Florida

Jan 2020

Keeping Up in the Race Against Bacterial Resistance
Florida Junior Science, Engineering, and Humanities
Symposium
Keynote Speaker
Gainesville, FL

Feb 2020

Too much of a good thing: Neurotoxic effects associated
with beta-lactams
Neurology Grand Rounds
UF Health Shands

Continuing Education Program
Gainesville, FL

Feb 2020	Too much of a good thing: Neurotoxic effects associated with beta-lactams Pharmacy Grand Rounds UF Health Shands Continuing Education Program Gainesville, FL
Jun 2021	The Role of Antimicrobial Stewardship in Enhancing Microbiology Lab Efforts American Society for Microbiology and Federation and European Microbiological Societies- World Microbe Forum Virtual presentation
Aug 2021	Beta-Lactam Therapeutic Drug Monitoring: Are we ready for primetime? IDWeek Virtual presentation
Aug 2022	Bedside to Bayesian: Making a Case for Personalized Beta-Lactam Dosing in Critical Illness Florida Society of Health System Pharmacy Orlando, FL
Dec 2022	Leveling Up: Implementation of beta-lactam therapeutic drug monitoring into clinical practice Amrita Vishwa Vidyapeetham School of Pharmacy Kochi, India
Mar 2023	Leveling Up: Implementation of beta-lactam therapeutic drug monitoring into clinical practice Royal Perth Hospital Perth, Australia Virtual Presentation
May 2023	Beta-Lactam TDM, Practical Protocols to Make it Work MAD-ID Workshop Orlando, FL
Jun 2023	Antimicrobial Resistance: Staying ahead of the game CATALySES College for Precollegiate Education and Training

University of Florida
Gainesville, FL

- Nov 2023** Using Pharmacokinetics to Optimize Antimicrobial Therapy Management
American College of Clinical Pharmacy
Dallas, TX
- Dec 2023** Why the Confusion? Demystifying β -Lactam Induced Neurotoxicity
American Society of Health-System Pharmacists
Anaheim, CA
- Jan 2024** Top Pharmacokinetic/Pharmacodynamic and Therapeutic Drug Monitoring of Antimicrobial Papers of 2023
Federation of Clinical Pharmacists in India
Virtual

PROFESSIONAL SERVICE

Professional Organizations

- 2002 – Present** Member
ASHP (American Society of Health System Pharmacists)
- 2004 – Present** Member
PLS (Phi Lambda Sigma) Pharmacy Leadership Society
- 2006 – Present** Member
American Society for Microbiology
- 2007 – Present** Member
ACCP (American College of Clinical Pharmacy)
ACCP ID-PRN- Newsletter subcommittee member 2016-2017
ACCP-ID PRN AID Subcommittee 2019
ACCP-Global Health PRN- Chair- Elect 2022-Present
- 2007 – Present** Member
SIDP (Society of Infectious Diseases Pharmacists)
Newsletter subcommittee member 2011-2012
Research subcommittee member 2012-2014
Diversity, Equity, and Inclusion Committee- Lead for Schools of Pharmacy Engagement Workgroup- 2020-Present

Institutional Committees

Aug 2008 – Jun 2010	Member Antimicrobial Subcommittee Los Angeles County Hospital (LAC+USC) Los Angeles, CA
Aug 2010 – Jul 2014	Co-Chair Antimicrobial Subcommittee The Brooklyn Hospital Center Brooklyn, NY
Aug 2010 – Jul 2014	Member Pharmacy and Therapeutics Committee The Brooklyn Hospital Center Brooklyn, NY
Aug 2010 – Jul 2014	Member Infection Control Committee The Brooklyn Hospital Center Brooklyn, NY
Jul 2013 – Jul 2014	Surgical Site Infection Committee The Brooklyn Hospital Center Brooklyn, NY
Aug 2014 – Dec 2015	Co-Chair Antimicrobial Subcommittee Scripps Green Hospital Scripps Memorial Hospital Encinitas San Diego, CA
Feb 2016 – Present	Member Anti-infective Subcommittee University of Florida Health Shands Gainesville, FL
Oct 2016 – Present	Diversity and Inclusion Taskforce University of Florida College of Pharmacy Gainesville, FL

SCHOLARLY ACTIVITIES/ RESEARCH

Poster Presentations

Venugopalan V, Thornton AC, Garvy BA, Feola DJ. Exposure to zidovudine plus sulfamethoxazole-trimethoprim alters peripheral lymphocyte function in HIV-infected patients. Southeastern Residency Conference. Athens, GA. April 2007.

Venugopalan V, Thornton AC, Garvy BA, Feola DJ. Exposure to zidovudine plus sulfamethoxazole-trimethoprim alters peripheral lymphocyte function in HIV-infected patients. American College of Clinical Pharmacy 2007 Annual Meeting Poster Session. Denver, CO. October 2007.

Venugopalan V, Hoven AD, Martin CA. Effect of vancomycin MIC on the need for alternative therapy in patients with methicillin resistant *Staphylococcus aureus* infections. Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. October 2008.

Bias T, Davanos E, Rahman S, **Venugopalan V**. Impact of gastric acidity on acquisition of cholera infection post gastric bypass. European Society of Clinical Microbiology and Infectious Diseases. London, United Kingdom. March 2012.

Bias T, **Venugopalan V**, Cha A. Incidence of antiretroviral drug interactions during hospitalization and the impact of clinical pharmacists in preventing these Interactions. The American Conference for the Treatment of HIV. Denver, CO. May 2012.

Venugopalan V, Cao Q, Singh P, Vincent WR. Comparison of predicted and measured vancomycin trough concentrations and estimation of target AUC/MIC for treatment of MRSA infections. Making a difference in Infectious Diseases. Orlando, FL. May 2012.

Beliard R, **Venugopalan V**. Impact of Vancomycin MIC on mortality in patients with Methicillin Resistant *Staphylococcus aureus* bacteremia. Making a Difference in Infectious Diseases. Orlando, FL. May 2012.

Bias T, Trustman N, Vincent WR, Berkowitz L, **Venugopalan V**. Impact of a pharmacy driven intervention to reduce time to first antibiotic in bacteremic patients. Accepted for presentation at Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. September 2012.

Su C, Hidayat L, **Venugopalan V**. Measuring the impact of peptide nucleic acid fluorescence in situ hybridization (PNA FISH) for identification of coagulase negative staphylococci from blood culture on vancomycin use. American Society of Health System Pharmacist Midyear Meeting and Exhibition. Las Vegas, NV. December 2012.

Fahim G, **Venugopalan V**, Hidayat L. Nephrotoxicity associated with intravenous colistin (Colistimethate sodium) Treatment at a community-teaching hospital. American Society of Health System Pharmacist Midyear Meeting and Exhibition. Las Vegas, NV. December 2012.

Nogid B, **Venugopalan V**, Bias T, Rahman S, Nicolau D. Double carbapenem therapy for carbapenemase-producing *Klebsiella pneumoniae*: From test tube to clinical practice. European Society of Clinical Microbiology and Infectious Diseases. Berlin, Germany. April 2013.

Venugopalan V, Trustman N, Manning N, Hashem NG, Berkowitz L, Hidayat L. Administration of a survey to evaluate the attitudes of housestaff physicians toward antimicrobial resistance and the antimicrobial stewardship program at a community teaching hospital. Making a Difference in Infectious Diseases. Orlando, FL. May 2013.

Hashem NG, Hidayat LK, Kondamudi VK, Berkowitz L, **Venugopalan V**. Management of skin and soft tissue infections (SSTIs) at a community teaching hospital using a severity-of-illness tool. Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver, CO. September 2013.

Su CP, Hidayat L, Rahman S, Oishi M, Noskow S, Gershen J, **Venugopalan V**. A prospective study on the use of a treatment algorithm with a severity-of-illness tool for skin and soft tissue infections (SSTIs) in the emergency department. Making a Difference in Infectious Diseases. Orlando, FL. May 2014.

Su CP, Hidayat L, Rahman S, **Venugopalan V**. Use of an anti-infective medication review process at hospital discharge to identify medication errors and optimize therapy. Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. September 2014.

Venugopalan V, DiGregorio R, Davanos. Development and Pilot of a standardized pharmacy residency inservice examination. American College of Clinical Pharmacy. Hollywood, Florida. October 2016.

McKamey L, Klinker K, **Venugopalan V**, Voils S, Borger S, Iovine N, Cherabuddi K. Clinical Utility of Cefepime for the Management of Bacteremia Secondary to AmpC Producing Organisms. Infectious Diseases Society of America. New Orleans, Louisiana. October 2016.

Bowden J, Klinker K, **Venugopalan V**. Implementation of a Beta-Lactam Therapeutic Drug Monitoring Program. Making a Difference in Infectious Diseases Pharmacotherapy (MAD-ID). Orlando, Florida. May 2017.

Premraj S, Cho H, Chen N, Guarderas J, Rodenas M, Borgert S, Klinker K, **Venugopalan V**. Retrospective Evaluation of Penicillin Allergy Skin Testing at a Large Academic Medical Center. Making a Difference in Infectious Diseases

Pharmacotherapy (MAD-ID). Orlando, Florida. May 2017.

Venugopalan V, Hiruy A, Rand K. Impact of Delayed Effective Antimicrobial Treatment in Hospitalized Patients with Gram-Negative Bacteremia. American Society of Microbiology. New Orleans, Louisiana. June 2017.

Premraj S, Garg M, Park H, Cherabuddi K, Klinker K, Borgert S, Lipori P, **Venugopalan V**. Use of a Severity Assessment System in Evaluating Management of ABSSSIs and Identification of Cost-Minimization Strategies at a Large Academic Hospital. European Congress of Clinical Microbiology and Infectious Diseases. Madrid, Spain. May 2018.

Hernandez S, **Venugopalan V**, Desear K, Santevecchi B, Ashton J, Cherabuddi K, Alshaer M, Peloquin C, Casapao A. Use of Therapeutic Drug Monitoring to Optimize Cefazolin Dosing in the Treatment of Methicillin-Susceptible *Staphylococcus aureus* (MSSA) Bacteremia. American Society of Health-System Pharmacists Clinical Midyear Meeting. December 2020. (Virtual)

Venugopalan V, Maranchick N, Hanai D, Hernandez YJ, Joseph Y, Gore A, Desear K, Peloquin C, Neely M, Felton T, Alshaer M. Evaluating the Area Under the Curve of Piperacillin and Vancomycin: Is Elevated Serum Creatinine a Marker for Nephrotoxicity in Combination Therapy? European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen, Denmark. April 2023. (Platform Presentation of Poster)

Venugopalan V, Santevecchi B, Rizvi S, Panesso D, Truc T, Miller W, Arias C, Desear K, Blanton J, Cherabuddi K, Iovine I, Maranchick N, Peloquin C, Alshaer M. Therapeutic Drug Monitoring to Optimize Cefazolin Dosing in Methicillin Susceptible *Staphylococcus aureus* Isolates Exhibiting the Inoculum Effect. European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen, Denmark. April 2023.

Manigaba K, Hahirwa I, Bitunga L, Munyemana JB, Inkindi A, **Venugopalan V**. International Virtual Mentorship and Multidisciplinary Collaboration: Advancing Antimicrobial Stewardship in Rwanda. MAD-ID. Orlando, FL.

Publications

Peer-reviewed

Venugopalan V, Martin CA. Selecting anti-infective agents for the treatment of bone infections: new anti-infective agents and chronic suppressive therapy. *Orthopedics*. 2007. Oct; 30(10): 832-4.

Venugopalan V, Smith KM, Young MH. Selecting anti-infective agents for the treatment of bone infections. *Orthopedics*. 2007. Sep; 30(9): 713-7.

Venugopalan V, Thornton AC, Steinke DT, Rapp RP, Romanelli F, and Feola DJ. Sulfamethoxazole-trimethoprim exposure alters *ex vivo* function of B lymphocytes

isolated from HIV-infected subjects receiving zidovudine. *Pharmacotherapy*. 2009; 29(4):373-82.

Venugopalan V, Shriner KA, Wong-Beringer A. Regulatory oversight and safety of probiotic use. *Emerging Infectious Diseases*. 2010;16(11):1661-5.

Bias T, Davanos E, Rahman S, **Venugopalan V**. Impact of gastric acidity on acquisition of cholera infection post gastric bypass. Abstract published in *Clinical Microbiology and Infection*. 2012;18(30):433.

Bias TE, Davanos E, Rahman SE, **Venugopalan V**. Impact of gastric acidity on the acquisition of cholera post gastric bypass. *Bariatric Surgical Practice and Patient Care* 2013;8(3):113-6.

Bias T, **Venugopalan V**, Berkowitz L, Cha A. Incidence of antiretroviral drug interactions during hospital course: The role of a pharmacist led antiretroviral stewardship program on reducing these errors. *Journal of Pharmacy Technology*. 2014;30(2):48-53.

Lynch K, **Venugopalan V**, Hidayat L. The effect of diabetes mellitus on the clinical and microbiological outcomes of patients with acute pyelonephritis. *American Journal of Infectious Diseases*. 2014;10(2):71-76.

Venugopalan V, Chen V, Hidayat L. Impact of an antimicrobial stewardship program (ASP) initiative on antibiotic optimization in patients with gram negative bacteremia. *Journal of Pharmacy and Pharmacology*. 2014;2(9):534-40.

Venugopalan V, Trustman N, Manning N, Hashem N, Berkowitz L, Hidayat L. Administration of a survey to evaluate the attitudes of house staff physicians towards antimicrobial resistance and the antimicrobial stewardship programme at a community teaching hospital. *Journal of Global Antimicrobial Resistance*. 2016; 4:21-27.

Hidayat L, Higgins C, **Venugopalan V**, Berrios-Colon E. Preparing students to enter the race for postgraduate training. *Journal of Pharmacy Practice*. 2016; 18:1-7.

Hashem N, Hidayat L, Berkowitz L, **Venugopalan V**. Management of Skin and Soft-Tissue Infections at a Community Teaching Hospital Using a Severity of Illness. *Journal of Antimicrobial Chemotherapy*. 2016;1(11):3268-3275.

Bias T, Vincent W, Trustman N, Berkowitz L, **Venugopalan V**. Impact of an Antimicrobial Stewardship Initiative in Reducing Time to Administration of Empiric Antibiotic Therapy in Hospitalized Patients with Bacteremia. *American Journal of Health-System Pharmacy*. 2017;74(7):511-519.

Venugopalan V, Nogid B, Le T, Rahman S, Bias T. Double Carbapenem Therapy (DCT) for Bacteremia Due to Carbapenem-Resistant *Klebsiella Pneumoniae* (CRKP): From Test Tube to Clinical Practice. *Infectious Diseases*. 2017; 49:867-870.

Buchanan P, Lee T, **Venugopalan V**, Tremblay E, Cannella A, Leyngold M. Extensively Drug-Resistant (XDR) *Pseudomonas aeruginosa* Sternal Osteomyelitis: Suggested Reconstructive Approach, and Novel Optimization of Antimicrobial Therapeutics. *Infectious Diseases in Clinical Practice*. 2018;26(1):11-15.

Su C, Hidayat L, Rahman S, **Venugopalan V**. Use of Anti-Infective Medication Review Process at Hospital Discharge to Identify Medication Errors and Optimize Therapy. *Journal of Pharmacy Practice*. 2018. 32(5):488-492.

McKamey L, **Venugopalan V**, Cherabuddi K, Borgert S, Voils S, Shah K, Klinker KP. Assessing Antimicrobial Stewardship Initiatives: Clinical Evaluation of Cefepime of Piperacillin-tazobactam in Patients with Bloodstream Infections Secondary to AmpC Producing Organisms. *Int J Antimicrob Agents*. 2018;52(5):719-723.

Venugopalan V, Manigaba K, Borgert S, Cope R, Peloquin C, Klinker K. Training a Drug to Do New Tricks: Insights into administration of meropenem as a continuous infusion. *Microbiology Insights*. 2018; 11:1-6.

Manigaba K, Borgert S, Klinker K, Cherabuddi K, **Venugopalan V**. SCAN: A Novel Approach for Vancomycin Time-Out. *Infect Control Hosp Epidemiol*. 2018;39(12):1501-1503.

Nys C, Cherabuddi K, **Venugopalan V**, Kenneth K. Clinical and Microbiologic Outcomes in Patients with Monomicrobial *Stenotrophomonas maltophilia* infections. *Antimicrob Agents Chemother*. 2019.63(11): e00788-19.

Voils SA, Shoulders BR, **Venugopalan V**. Letter to the editor (Infection after penetrating brain injury). *J Trauma Acute Care Surg*. 2019; 88(3):e119.

Aloisamy S., Jorgensen SCJ, Melvin S, Mynatt RP, Carlson T, Garey KW, Allen D, **Venugopalan V**, Veve M, Athans V, Saw S, Yost C, Rybak MJ. Real-world multi-center experience of meropenem-vaborbactam in patients treated for serious Gram-negative bacterial infections. *Open Forum Infectious Diseases*. 2020.7(3): ofaa051.

Shoulders BR, Casapao AM, **Venugopalan V**. An Update on Existing and Emerging Data for Meropenem-Vaborbactam. *Clin Ther*. 2020;42(4):692-702.

Alshaer MH, Rubido E, Cherabuddi K, **Venugopalan V**, Klinker K, Peloquin C. Early therapeutic monitoring of β -lactams and associated therapy outcomes in critically ill patients. *J Antimicrob Chemother*. 2020;75(12):3644-3651.

Al-Shaer MH, Neely MN, Liu J, Cherabuddi K, **Venugopalan V**, Rhodes NJ, Klinker K, Scheetz MH, Peloquin CA. Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing. *Antimicrob Agents Chemother*. 2020; 75(12):3644-3651.

Alosaimy S, Lagnf AM, Morrisette T, Scipione MR, Zhao JJ, Jorgensen SCJ, Mynatt R, Carlson TJ, Jo J, Garey KW, Allen D, DeRonde K, Vega AD, Abbo LM, **Venugopalan V**, Athans V, Saw S, Claeys KC, Miller M, Molina KC, Veve M, Kufel WD, Amaya L, Yost C, Ortwine J, Davis SL, Rybak MJ. Real-world, Multicenter Experience with Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant *Enterobacterales* and *Pseudomonas aeruginosa*. *Open Forum Infect Dis*. 2021. 8(8):ofab371.

Koro M, Borgert S, Abbott A, **Venugopalan V**. Evaluation of Susceptibility Patterns in Uropathogens and Empiric Antibiotic Therapy in the Emergency Department. *Hosp Pharm*. 2021;56(6):745-750.

Vu CH, **Venugopalan V**, Santevecchi BA, Voils SA, Ramphal R, Cherabuddi K, DeSear K. Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase-producing *Enterobacterales* bloodstream infections (REDUCE-BSI). *Antimicrob Steward Healthc Epidemiol*. 2022 Mar 11;2(1):e39.

Venugopalan V, Crawford C, Ho K, Klinker K, Cherabuddi K, DeSear K. Economic Burden of Uncomplicated Skin and Soft Tissue Infections Due to Over Utilization of Diagnostics Tests and Excess Admissions. *J Pharm Pract*. 2022. 35 (5):675-679.

Venugopalan V, Hamza M, Santevecchi B, DeSear K, Cherabuddi K, Peloquin C, Al-Shaer M. Implementation of a Beta-Lactam Therapeutic Drug Monitoring Program: Experience from a Large Academic Medical Center. *Am J Health Syst Pharm*. 2022; 79(18): 1586-1591.

Alosaimy S, Lagnf AM, Hobbs ALV, Mubarez M, Kufel WD, Morrisette T, Polisetty RS, Li D, Veve MP, Simon SP, Truong J, Finch N, **Venugopalan V**, Rico M, Amaya L, Yost C, Cubillos A, Chandler E, Patch M, Smith IMK, Biagi M, Wrin J, Moore WJ, Molina KC, Rebold N, Holger D, Kunz Coyne AJ, Jorgensen S, Witucki P, Tran NN, Davis SL, Sakoulas G, Rybak MJ. Nephrotoxicity of Vancomycin in Combination with Beta-lactam Agents: Ceftolozane-tazobactam vs. Piperacillin-tazobactam. *Clin Infect Dis*. 2022. Epub ahead of print.

Kunz Coyne AJ, Alshaer M, Casapao AM, **Venugopalan V**, Isache C, Ferreira J, Jankowski CA. Effectiveness and Safety of Beta-Lactam Antibiotics with and without Therapeutic Drug Monitoring in Patients with *Pseudomonas aeruginosa* Pneumonia or Bloodstream Infection. *Antimicrob Agents Chemother*. 2022;66(10).

Venugopalan V, Casaus D, Kainz L, Slaton CN, Hurst N, Bruzzzone M, Hu C, Sword G, Cherabuddi K, Iovine N, Liu J, Scheetz MH, Rhodes N, Maranchick N, Peloquin CA,

Klinker K, Alshaer MH. Use of therapeutic drug monitoring to characterize cefepime-related neurotoxicity. *Pharmacotherapy*. 2023;43(1):6-14.

Branton AC, Vu CH, **Venugopalan V**, Santevecchi BA, Cherabuddi K, Ramphal R, Manohar T, Desear KE. Re-evaluation of cefepime or piperacillin/tazobactam to decrease use of carbapenems in ESBL-producing Enterobacterales urinary tract infections (REDUCE-UTI). *JAC Antimicrob Resist*. 2023 Mar 17;5(2)

Allen JM, Cavanaugh TM, Hathorn T, Awunti M, Whitner C, **Venugopalan V**, Ozimek M, Butler LM, Buring SM. Exploring trends in social vulnerability for pharmacy students at a large public university. *Am J Pharm Educ*. 2023. Epub ahead of print.

Garg M, **Venugopalan V**, Vouri SM, Diaby V, Iovine NM, Park H. Oral Fluoroquinolones and Risk of Aortic Aneurysm or Dissection: A Nationwide Population-Based Propensity Score Matched Cohort Study. *Pharmacotherapy*. 2023. Epub ahead of print.

Maranchick NF, Trillo-Alvarez C, Kariyawasam V, **Venugopalan V**, Kwara A, Rand K, Peloquin CA, Alshaer MH. A Randomized Clinical Trial of Bayesian-Guided Beta-Lactam Infusion Strategy and Associated Bacterial Resistance and Clinical Outcomes in Patients With Severe Pneumonia. *Ther Drug Monit*. 2024;46(1):95-101.

Maranchick NF, Trillo-Alvarez C, Kariyawasam V, **Venugopalan V**, Kwara A, Rand K, Peloquin CA, Alshaer MH. A Randomized Clinical Trial of Bayesian-Guided Beta-Lactam Infusion Strategy and Associated Bacterial Resistance and Clinical Outcomes in Patients With Severe Pneumonia. *Ther Drug Monit*. 2024;46(1):95-101.

Venugopalan V, Maranchick N, Hanai D, Hernandez YJ, Joseph Y, Gore A, Desear K, Peloquin C, Neely M, Felton T, Shoulders B, Alshaer M. Association of piperacillin and vancomycin exposure on acute kidney injury during combination therapy. *JAC Antimicrob Resist*. 2024;6(1):dlad157. doi: 10.1093/jacamr/dlad157.

Book Chapters

Venugopalan V, Hidayat L. Lower Respiratory Tract Infections, Primary Care (2nd Edition), Edited by Singleton JK, New York, Springer Press, 1999.

Hidayat L, **Venugopalan V**. Urinary Tract Infections, Primary Care (2nd Edition), Edited by Singleton JK, New York, Springer Press, 1999.

Su CP, **Venugopalan V**. Tuberculosis, Primary Care (2nd Edition), Edited by Singleton JK, New York, Springer Press, 1999.

Venugopalan V, Klinker K. Cell Wall Inhibitors. *Lippincott Illustrated Reviews: Pharmacology* (7th Edition), Edited by Wolters Kluwer, Lippincott-Raven Publishers, 2018.

Venugopalan V. Skin and Soft-Tissue Infections. PharmacotherapyFirst: A Multimedia Learning Resource. American Pharmacists Association. 2018.

Research Grants

Title- Effect of subinhibitory concentrations of linezolid, clindamycin, and vancomycin on staphylokinase Production by Community-Associated Methicillin-Resistant *Staphylococcus aureus* and its potential Implication on Influenza A/*Staphylococcus aureus* co-infections

Role- Principal Investigator; Senior Mentor- Annie Wong-Beringer, Pharm.D.

Funding and Source- \$ 10,000; ACCP New Pharmacy Faculty Research Award

Status- Not funded, 2010 Nov

Title- Clinical and Microbiological Outcomes in Uncontrolled Diabetics with Acute Pyelonephritis

Role- Co-investigator; Principal Investigator- Levita Hidayat, Pharm.D.

Funding and Source- \$10,000; AACP New Investigator Award

Status- Not funded, 2013 Jan

Title- The development and prospective evaluation of an algorithm for the management of SSTIs using a severity of illness tool

Role- Principal Investigator

Funding and Source- \$20,000; ASHP New Investigator Grant

Status- Not funded, 2013 Apr

Title- Effect of Subinhibitory Concentrations of Linezolid, Tedizolid, Clindamycin, and Vancomycin on Staphylokinase Production by Community-Associated Methicillin Resistant *Staphylococcus aureus* and its Potential Implication on Influenza A/*Staphylococcus aureus* co-infections

Role- Principal Investigator; Senior Mentor- Ashley Brown, PhD

Funding and Source- \$13,815; Shands Quasi Endowment Grant

Status- Funded, 2017 Jan

Title- Virtual Microbiology Tour

Role- Principal Investigator

Funding and Source- \$2,500; Society of Infectious Diseases Pharmacists (SIDP) Education Grant

Status- Funded, 2021 Mar

Title- Prevalence of Cefazolin Inoculum Effect in Methicillin Susceptible *Staphylococcus aureus* (MSSA)

Role- Principal Investigator

Funding and Source- \$14,400; Shands Quasi Endowment Grant

Status- Funded, 2021 May

Title- Nursing Home and Long-Term Care Facility Strike Team and Infrastructure Project

Role- Co-Investigator

Funding and Source- \$ 1,250,000; Florida Department of Health

Status- Funded, 2022 Oct

AWARDS AND MERITS

ASSP (Associated Students of the School of Pharmacy) Pharmacy Year 4 Preceptor of the Year. University of Southern California, School of Pharmacy- 2009

ASSP (Associated Students of the School of Pharmacy) Pharmacy Year 4 Preceptor of the Year. University of Southern California, School of Pharmacy - 2010

The Brooklyn Hospital Center Pharmacy Residency Preceptor of the Year- 2012
New York City Society of Health System Pharmacist (NYCSHP) Best Practice Award 2013: "Impact of a Pharmacy Driven Intervention to Reduce Time to Initiation of Antibiotic Therapy in Bacteremic Patients"

Best Clinical Practice Research Paper. University of Florida, College of Pharmacy- 2017

Faculty Advisor of the Year. University of Florida, College of Pharmacy- 2018

Exemplary Clinician of the Year. University of Florida, College of Pharmacy- 2019

Teacher Service Award. University of Florida, College of Pharmacy- 2021

Exemplary Teaching Award. University of Florida, College of Pharmacy- 2022

OTHER

ASHP PGY2 Infectious Diseases Practitioner Accreditor-
2021 Participated in one residency accreditation
2022 Participated in two residency accreditations



Signature

01/24/24

Date